Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01300962
Title Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center

Her2-receptor positive breast cancer

breast cancer


Buparlisib + Capecitabine + Lapatinib

Buparlisib + Capecitabine + Trastuzumab

Buparlisib + Capecitabine

Alpelisib + Capecitabine

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.